Voya Investment Management LLC trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 63.3% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 442,203 shares of the medical research company's stock after selling 761,095 shares during the period. Voya Investment Management LLC owned approximately 0.08% of Amgen worth $115,256,000 as of its most recent filing with the SEC.
Other institutional investors have also made changes to their positions in the company. Capital World Investors lifted its holdings in Amgen by 1,292.0% during the 4th quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock valued at $1,693,042,000 after purchasing an additional 6,029,058 shares during the last quarter. Norges Bank acquired a new stake in shares of Amgen in the 4th quarter valued at $1,541,991,000. Capital International Investors increased its stake in shares of Amgen by 40.1% in the 4th quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock valued at $3,182,843,000 after buying an additional 3,495,503 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Amgen by 25.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock worth $3,441,909,000 after acquiring an additional 2,672,975 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Amgen during the fourth quarter valued at $401,913,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several brokerages have weighed in on AMGN. Royal Bank of Canada reissued an "outperform" rating and set a $324.00 price objective on shares of Amgen in a report on Friday, January 24th. Citigroup reaffirmed a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Piper Sandler Companies restated an "overweight" rating and issued a $310.00 price target on shares of Amgen in a research report on Thursday, January 2nd. UBS Group increased their price target on shares of Amgen from $315.00 to $319.00 and gave the company a "neutral" rating in a research report on Monday, April 14th. Finally, Truist Financial cut their target price on shares of Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a report on Wednesday, January 8th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $310.57.
Check Out Our Latest Research Report on AMGN
Amgen Stock Up 0.8 %
Shares of NASDAQ:AMGN traded up $2.25 during midday trading on Monday, hitting $283.09. The stock had a trading volume of 2,082,362 shares, compared to its average volume of 2,788,770. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The business's 50-day simple moving average is $301.52 and its 200-day simple moving average is $292.42. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a market cap of $152.20 billion, a P/E ratio of 37.50, a PEG ratio of 2.63 and a beta of 0.59.
Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.
Amgen Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.36%. Amgen's dividend payout ratio (DPR) is 126.09%.
Insider Buying and Selling at Amgen
In related news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. This represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock worth $20,644,335 over the last ninety days. Insiders own 0.69% of the company's stock.
About Amgen
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
